Evidence Level
Emerging
Omega-7 research is still in its early stages but shows promising cardiometabolic effects. The foundational mechanistic study by Cao et al. (2008) in Cell identified palmitoleic acid as a lipokine — a fat-derived hormone that communicates between adipose tissue and the liver. Bernstein et al. (2014) conducted the most cited clinical trial, demonstrating significant triglyceride and CRP reductions with purified palmitoleic acid supplementation. Epidemiological data from Mozaffarian et al. (2010) in Annals of Internal Medicine found that circulating trans-palmitoleate levels were associated with lower metabolic syndrome risk. More large-scale RCTs are needed to establish definitive cardiovascular endpoints.